Sharemaestro Newsreel

Amgen stock hits all-time high at 398.65 USD

Amgen Inc. stock has reached an all-time high of $398.65, currently trading at $403.13, giving the biotechnology giant a market capitalization of $210.5 billion. The surge reflects investor confidence following strong performance, with the stock price increasing by 37.01% over the past year and …

Amgen (AMGN) Could Be 8% Overvalued Following Raised 2026 Guidance

Amgen (AMGN) reported strong Q2 2026 results, beating analyst expectations and raising its full-year revenue and earnings guidance. Despite a significant share price increase, Simply Wall St's narrative valuation suggests the stock is 8.3% overvalued at $390.02, with a fair value of $359.98, while …

Prediction: AbbVie Will End The Year at This Price

24/7 Wall St. predicts AbbVie (ABBV) will end the year with a "buy" rating and a price target of $297.71, representing a 20.92% upside from its current price. This optimistic outlook is driven by the strong performance of drugs like Skyrizi and Rinvoq, which …

Amgen gains after strong quarterly results and continued product momentum

Amgen's shares rose approximately 4% after the biotechnology company announced second-quarter 2026 results that exceeded Wall Street expectations. The company reported adjusted earnings per share of $6.29 and revenue of $10.05 billion, driven by a 10% year-over-year increase in total revenue and double-digit sales …

Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks

A senior source close to the matter denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks, contradicting earlier reports of a potential $400 billion combination. This denial comes after AstraZeneca's shares dropped following the initial reports, while Bristol Myers Squibb's stock …

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Novo Nordisk, the Danish maker of Ozempic, experienced a significant boom in 2024, becoming Europe's largest company by market capitalization due to its successful GLP-1 weight-loss drugs. However, the article suggests that despite this success, the company may have lost its leading edge to …

JPMorgan Adjusts Price Target on Merck & Co. to $150 From $140, Maintains Overweight Rating

JPMorgan has increased its price target for Merck & Co. (NYSE:MRK) to $150 from $140, while reaffirming an Overweight rating on the stock. This adjustment indicates a positive outlook on the company's future performance.

Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data

Novo Nordisk's CEO acknowledged recent R&D setbacks, including mixed data for CagriSema and the failure of ziltivekimab in a phase 3 cardiovascular study. Despite CagriSema missing an endpoint in a Type 2 diabetes trial compared to Eli Lilly's tirzepatide, Novo remains optimistic about its …

Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Eli Lilly has raised its full-year revenue forecast after reporting better-than-expected quarterly results, driven by strong demand for its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound. The company's shares rose 5% in premarket trading, reassuring investors about its market position despite increasing competition …

AstraZeneca climbs Wednesday, outperforms market

Shares of AstraZeneca PLC (AZN) rose 2.52% to £120.36 on Wednesday, outperforming the FTSE 100 Index, which increased by 0.08%. The company's stock closed 23.49% below its 52-week high of £157.32.

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

A senior source close to the matter has stated that there are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger, dispelling recent reports of a mega deal. AstraZeneca's shares initially slid after the Financial Times reported on potential talks …

Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom

Eli Lilly's new oral GLP-1 treatment, Foundayo, reported Q2 sales of $98 million, significantly trailing Novo Nordisk's rival Wegovy pill. Despite this, positive trends for Foundayo in the U.S. and strong international potential were noted. Meanwhile, Lilly's injectable diabetes and obesity medicines, Mounjaro and …

Gilead Raised HIV Guidance on Its Q2 Earnings Call. Here’s What That Means for GILD Stock.

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly significantly surpassed its second-quarter earnings and revenue estimates, prompting an increase in its full-year sales forecast. This strong performance was primarily driven by the surging demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro. The company also reported initial sales from …

Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences announced its second quarter 2026 financial results, reporting a 10% year-over-year revenue growth in its base business, driven by its HIV portfolio, Trodelvy, and Livdelzi. The company reported diluted loss per share of $(8.45) and non-GAAP diluted loss per share of $(6.75), …

AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Amgen reported strong second-quarter 2026 financial results, with total revenues increasing 10% to $10.1 billion and product sales growing 9%, driven by volume. The company saw significant growth in several key products like Repatha, EVENITY, and TEPEZZA, and provided updates on its extensive pipeline, …

Central Pacific Bank Trust Division Sells 4,628 Shares of AbbVie Inc. $ABBV

Central Pacific Bank Trust Division significantly reduced its stake in AbbVie Inc. by 44.5% in the second quarter, selling 4,628 shares and retaining 5,766 shares valued at $1.45 million. Despite this sale, AbbVie reported strong second-quarter results with revenue up 10.2% and adjusted EPS …

Canandaigua National Bank & Trust Co. Acquires New Stake in AbbVie Inc. $ABBV

Canandaigua National Bank & Trust Co. has acquired a new stake in AbbVie Inc., purchasing 27,540 shares valued at approximately $6.93 million. This comes as AbbVie reported strong second-quarter results, exceeding analyst expectations with revenue up 10.2% year-over-year and solid EPS. The company also …

‘No discussions’ ongoing for AstraZeneca-BMS merger: Reuters

Reuters reported that there are no ongoing discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting an earlier Financial Times report. The Financial Times report had caused AstraZeneca's stock to drop, while the Reuters news led to a rebound for AZ …

CVS and Lilly plan same-day Zepbound pickup by early Q4

CVS Health is expanding its direct-to-consumer weight management offerings, focusing on GLP-1 medications, by combining digital care and in-store support. A new collaboration with Eli Lilly will enable eligible Zepbound and Foundayo patients to view transparent pricing in the CVS Health app for potential …

new drugs are rewriting Biogen’s story - News Freedom Broker

Freedom Broker analysts have reaffirmed their "Buy" rating on Biogen Inc. (BIIB) and increased the target price from $245 to $255, citing the company's successful diversification into new drug portfolios. The acquisition of Apellis Pharmaceuticals has been a turning point, with innovative product revenues …

Eli Lilly shares rise on revenue beat, raised outlook

Eli Lilly's shares rose nearly 7% after the drugmaker reported second-quarter revenues of $22.97 billion, exceeding Wall Street expectations, and raised its full-year 2026 revenue outlook to $85 billion to $87 billion. The strong performance was primarily driven by robust demand and sales increases …

Merck & Co., Inc. Q2 Earnings Call Highlights

Merck & Co., Inc. reported Q2 revenue of $16.6 billion, a 5% increase year-over-year, primarily driven by strong oncology, animal health, and new product sales. Despite a $0.13 per-share loss due to a $5.7 billion charge from the Terns Pharmaceuticals acquisition, the company raised …

California High Court’s Gilead Ruling Marks Tort Law Sea Change

The California Supreme Court has issued a landmark ruling shielding Gilead Sciences Inc. from liability related to developing and marketing its drugs, even if safer alternatives exist within its pipeline. This decision, described as a "monumental shift," provides an exception from the duty of …

Bristol-Myers falls on report there are no talks going on with AstraZeneca

Bristol-Myers Squibb's stock fell 1.4% in premarket trading following a report that there are no ongoing discussions with AstraZeneca regarding a potential deal. Conversely, AstraZeneca's shares rose by 5.6% after the news. The report explicitly stated that no deal ever existed between the two …

Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Mira Pharmaceuticals Inc (MIRA) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average at 8.10. Analysts provide a consensus price target of $3.00, suggesting a significant upside of +109.79%. There are no analysts providing individual ratings for MIRA as …

Nurix Receives $10M Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader SAR448272

Nurix has received a $10 million milestone payment from Sanofi following the initiation of a Phase 1 clinical trial for SAR448272/NX-3911, an oral small-molecule degrader targeting STAT6. This payment brings Nurix's total earnings from the 2019 collaboration to approximately $139 million, with potential for …

Key facts: Merck & Co., Inc. Q2 Sales $16.6B; sac-TMT Advances

Merck & Co. (MRK) reported Q2 sales of $16.6 billion, a 5% year-over-year increase, with Keytruda sales reaching $8.4 billion and Winrevair at $588 million, up 75%. The company posted a GAAP net loss of $1.34 billion and an adjusted loss of $0.13 per …

Eli Lilly and Company elevates Gaurav Mehta to AVP, CMO & Strategic Capabilities

Eli Lilly and Company has promoted Gaurav Mehta to Associate Vice President, CMO, and Strategic Capabilities. Mehta previously served as Executive Director, Marketing and Strategic Capabilities, and has a strong background in marketing leadership roles across various companies including Noise, Zupee, GirnarSoft, OLX South …

Argus Upgrades Bristol-Myers Squibb to Buy From Hold, Price Target is $75

Argus has upgraded Bristol-Myers Squibb (BMY) to a "Buy" rating from "Hold," setting a new price target of $75. The company currently holds an average rating of "overweight" with a mean price target of $66 among analysts. The full MT Newswires article with further …

Pfizer Stock Slips Despite Earnings Beat and $2.5 Billion Cuts

Gilead Sciences (GILD) Stock Price Reflects R And D Shock Not Sales Weakness

MERCK & CO INC : JP MORGAN RAISES TARGET PRICE TO $150 FROM $140

JP Morgan has raised its target price for Merck & Co Inc (MRK.N) to $150 from the previous $140. This adjustment reflects an updated outlook from the financial institution regarding the pharmaceutical company's stock performance. The news was reported by Reuters.

Novo Nordisk Stock Drops on Wegovy Shortfall

Novo Nordisk's U.S.-traded shares fell over 6% due to lower-than-expected sales of its new Wegovy weight-loss pill and a disappointing study result for a next-generation drug. This decline occurred despite the company pre-announcing improved overall results and an upgraded full-year 2026 financial outlook. Second-quarter …

Glenmede Trust Co. NA Acquires 8,680 Shares of Novartis AG $NVS

Glenmede Trust Co. NA increased its stake in Novartis AG (NVS) by 16% in the first quarter, purchasing 8,680 shares to bring its total holdings to 63,066 shares valued at $9.6 million. Other institutional investors also adjusted their positions in Novartis, which has a …

AMGEN INC : JEFFERIES RAISES TARGET PRICE TO $385 FROM $346

Jefferies has increased its target price for Amgen Inc. (AMGN) to $385 from $346. This information, provided by Reuters, indicates an analyst's revised valuation for the pharmaceutical company. The article also includes a disclaimer stating that the content reflects only the author's opinion and …